The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 
Chemical Compound Review

SureCN667785     (3,3,5-trimethylcyclohexyl) 5...

Synonyms: AC1L1TST, AC1Q60R6, 120551-59-9, 3,3,5-trimethylcyclohexyl 5-oxoprolinate
 
 
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.
 

Disease relevance of CRILVASTATIN

  • In hamsters fed on a lithogenic diet for 8 weeks, crilvastatin treatment (200 mg/day per kg body weight) did not change plasma lipid levels, failed to improve bile parameters and did not prevent gallstone formation [1].
 

High impact information on CRILVASTATIN

  • 4. Crilvastatin not only acts by stimulating LDL-cholesterol uptake by hepatocytes, but also by enhancing the catabolism of LDL-cholesterol in bile salts and probably by stimulating HDL and/or bile component secretion [2].
  • 2. The experiments were carried out for 20 h, each well contained 4.2 x 10(5)/cm2 Hep G2 cells or 0.5 x 10(5)/Cm2 human hepatocytes, 130 microM ursodeoxycholate, 0.68 microCi or 1.59 microCi unesterified human [14C]-LDL-cholesterol, crilvastatin or simvastatin at 0 or 50 microM (both cell types) or 300 microM (Hep-G2 cells) [2].
  • Crilvastatin enhanced both the level of apo A1 secreted by the Hep G2 cells and the level of APF, a high density lipoprotein (HDL) and biliary apoprotein [2].
  • Crilvastatin, a new 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, inhibits cholesterol absorption in genetically hypercholesterolemic rats [3].
  • In rats with a previous high cholesterolemia, crilvastatin also enhanced cholesterol 7 alpha-hydroxylase activity and did not increase liver acyl coenzyme A:cholesterol acyl transferase activity [4].
 

Associations of CRILVASTATIN with other chemical compounds

References

  1. Reduced cholesterol absorption in hamsters by crilvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Hajri, T., Chanussot, F., Férézou, J., Riottot, M., Lafont, H., Laruelle, C., Lutton, C. Eur. J. Pharmacol. (1997) [Pubmed]
  2. Differences in hypolipidaemic effects of two statins on Hep G2 cells or human hepatocytes in primary culture. Clerc, T., Sbarra, V., Domingo, N., Rault, J.P., Diaconescu, N., Moutardier, V., Hasselot, N., Lafont, H., Jadot, G., Laruelle, C., Chanussot, F. Br. J. Pharmacol. (1996) [Pubmed]
  3. Crilvastatin, a new 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, inhibits cholesterol absorption in genetically hypercholesterolemic rats. Hajri, T., Férézou, J., Laruelle, C., Lutton, C. Eur. J. Pharmacol. (1995) [Pubmed]
  4. Mechanisms of action in the liver of crilvastatin, a new hydroxymethylglutaryl-coenzyme A reductase inhibitor. Clerc, T., Jomier, M., Chautan, M., Portugal, H., Senft, M., Pauli, A.M., Laruelle, C., Morel, O., Lafont, H., Chanussot, F. Eur. J. Pharmacol. (1993) [Pubmed]
 
WikiGenes - Universities